Botulinum toxin A - Medy-Tox

Drug Profile

Botulinum toxin A - Medy-Tox

Alternative Names: Botulift; Cunox; KbtxA; Meditoxin; MT 10107; MT 10109; Neuronox; Siax

Latest Information Update: 31 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medy-Tox
  • Developer Medytox
  • Class Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Glabellar lines; Muscle spasticity; Spasm
  • Phase III Torticollis
  • Phase II Hypertrophy
  • Phase I Hyperhidrosis; Overactive bladder

Most Recent Events

  • 16 Apr 2018 Medy-Tox initiates a phase I trial for Healthy volunteers in South Korea , (NCT03547141)
  • 20 Mar 2018 Phase-I clinical trials in Hyperhidrosis (In volunteers) in South Korea (Intradermal) (NCT03647982)
  • 09 Mar 2018 Medy-Tox plans a phase III trial for Benign masseteric hypertrophy in March 2018 (NCT03452345)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top